Tumour biology and pathology

9P - Clinical validation of an NGS-based assay for detecting multiple genomic alterations in Chinese patients with non-small cell lung cancer

Authors
  • H. Ge (Xiamen, China)
  • X. Chen (Fuzhou, China)
  • L. Ruan (Xiamen, China)
  • Q. Gao (Xiamen, China)
  • X. Yang (Xiamen, China)
  • W. Shi (Xiamen, China)
  • X. Li (Xiamen, China)
  • G. Zhu (Xiamen, China)
Speakers
  • H. Ge (Xiamen, China)

Previous ePoster
8P - Role of chemokines in resectable non-small cell lung cancer (NSCLC)

Next ePosters
10P - The prevalence and prognostic significance of JAK2 mutation subtypes in non-small cell lung cancer from Chinese populations
12P - Clinicopathologic characteristics of patients with TP63 mutations in Chinese non-small cell lung cancer
13P - The micro-environmental cross talk between mast cells and lung cancer cells through cell-to-cell contact
14P - The characteristics of MET exon 14 skipping mutations in Chinese non-small cell lung cancer: A retrospective analysis
No ePoster preview available
15P - TTF1 status in non-small cell lung cancer adenocarcinoma: A prognostic factor
18P - Immunohistochemical expression of PD-L1 in early and late stage non-small cell lung cancer: Correlation with clinicopathological and molecular features
22P - Paclitaxel/ carboplatin/ bevacizumab in non-small cell lung cancer patients induces peripheral effector CD8 T cell proliferation that could be prone for treatment with checkpoint inhibitors
24P - A new bioinformatic pipeline allows the design of small, targeted gene panels for efficient TMB estimation
29P - Pretreatment T790M mutation detection by ultrasensitive PCR assay as predictor of efficacy in non-small lung cancer (NSCLC) patients treated with 1st or 2nd generation EGFR tyrosine kinase inhibitors (TKIs)
30P - Prognostic significance of IGF-1 signaling pathway in patients with advanced non-small cell lung cancer